The genomic region encoding the miR-17-92 microRNA (miRNA) cluster is often amplified in lymphoma and other cancers, and cancer cells carrying this amplification have higher expression of miRNA in this cluster. Retroviral expression of miR-17-92 accelerates c-Myc-induced lymphoma development, but precisely how higher expression of miR-17-92 promotes lymphomagenesis remains unclear. Here we generated mice with higher expression of miR-17-92 in lymphocytes. These mice developed lymphoproliferative disease and autoimmunity and died prematurely. Lymphocytes from these mice showed more proliferation and less activation-induced cell death. The miR-17-92 miRNA suppressed expression of the tumor suppressor PTEN and the proapoptotic protein Bim. This mechanism probably contributed to the lymphoproliferative disease and autoimmunity of miR-17-92-transgenic mice and contributes to lymphoma development in patients with amplifications of the miR-17-92 coding region.
The genomic region encoding the miR-17-92 microRNA (miRNA) cluster is often amplified in lymphoma and other cancers, and cancer cells carrying this amplification have higher expression of miRNA in this cluster. Retroviral expression of miR-17-92 accelerates c-Myc-induced lymphoma development, but precisely how higher expression of miR-17-92 promotes lymphomagenesis remains unclear. Here we generated mice with higher expression of miR-17-92 in lymphocytes. These mice developed lymphoproliferative disease and autoimmunity and died prematurely. Lymphocytes from these mice showed more proliferation and less activation-induced cell death. The miR-17-92 miRNA suppressed expression of the tumor suppressor PTEN and the proapoptotic protein Bim. This mechanism probably contributed to the lymphoproliferative disease and autoimmunity of miR-17-92-transgenic mice and contributes to lymphoma development in patients with amplifications of the miR-17-92 coding region.
After antigen engagement, antigen receptors on lymphocytes trigger signaling pathways involving the transcription factor NF-kB, phosphtidylinositol-3-OH kinase, the serine-threonine kinase Akt, mitogen-activated protein kinases, the c-Myc proto-oncogene product, and the Bcl-2 family of apoptosis regulators. These pathways lead to lymphocyte activation, proliferation and survival 1 . Studies have shown that alterations in these molecular pathways are critical to the development of autoimmune disease and lymphoma 1, 2 . The gene encoding PTEN (A001941), an inhibitor of the phosphtidylinositol-3-OH kinase pathway, is often mutated in human lymphomas, and this mutation predisposes humans to both autoimmunity and cancer [3] [4] [5] . In mice with T lymphocyte-specific loss of PTEN, both central and peripheral tolerance are compromised and the mice develop autoimmunity and T cell lymphoma with a latency of a few weeks 6 . Bim (A003649), a Bcl-2 homology domain 3-only proapoptotic member of the Bcl-2 family, is another example of a molecule at the crossroads of autoimmunity and lymphoma. Bim is essential for the deletion of self-reactive thymocytes, mature T cells, and immature and mature B cells. Bimdeficient mice develop autoimmunity with a latency of 6-12 months, and Bim deficiency accelerates c-Myc-induced lymphomagenesis [7] [8] [9] [10] [11] . Notably, loss of even a single allele of the gene encoding either PTEN or Bim is sufficient to cause measurable biological effects, which suggests that these proteins function over a narrow range of concentrations in physiological conditions and that small changes in their concentrations have severe biological consequences 7, 12 .
MicroRNA (miRNA) molecules have emerged as important factors in the post-transcriptional control of intracellular protein concentrations in metazoan organisms. These RNA molecules of approximately 22 nucleotides pair with mRNA molecules transcribed from protein-encoding genes and specify the degradation or translational repression of the mRNA molecules 13 . The miRNA molecules have distinct temporal and spatial expression patterns and regulate a diverse range of physiological processes, including hematopoiesis, developmental timing, cell differentiation and proliferation, apoptosis, and organ development 14, 15 . Expression profiling studies have detected specific miRNA expression 'signatures' in a variety of human cancers, and miRNA genes are frequently located at genomic regions associated with carcinogenesis, which suggests that miRNA molecules may be involved in cell transformation [16] [17] [18] .
The miR-17-92 miRNA cluster is located at human chromosome 13q31 in a genomic region that is often amplified in lymphomas and other cancers, and cancer cells have high expression of the mature miRNA molecules encoded by this locus [18] [19] [20] [21] . Retroviral expression of this miRNA cluster in the hematopoietic system accelerates the onset of c-Myc-mediated lymphomagenesis in a transgenic mouse model involving bone marrow reconstitution 22 . To elucidate the mechanism by which the miR-17-92 cluster promotes lymphomagenesis, we generated mice with higher miR-17-92 expression in lymphocytes. We found that PTEN mRNA and Bim mRNA were direct targets of miRNA molecules in the miR-17-92 cluster, that PTEN and Bim protein expression was downregulated after constitutive and moderate overexpression of miR-17-92 miRNA, and that miR-17-92-transgenic mice developed a lymphoproliferative disease and autoimmunity.
RESULTS

Transgenic expression of miR-17-92 miRNA
The human miR-17-92 transcript encoded on chromosome 13 is the precursor of seven miRNA molecules (miR-17-5p, miR-17-3p, miR-18a, miR-19a, miR-20a, miR-19b and miR-92). Additionally, this cluster is homologous to the miR-106a-363 cluster on human chromosome X and the miR-106b-25 cluster on human chromosome 7. Together, these three clusters contain 15 miRNA stem-loop structures, giving rise to 14 distinct mature miRNA molecules in five microRNA families; the members in each family have identical 'seed regions' (Supplementary Fig. 1 online) . This genomic organization is highly conserved in all vertebrates from which complete genome sequences are available 23 , and many of the encoded miRNA molecules are broadly expressed in mouse tissues and cells, with relatively high expression in lymphocytes and embryonic stem cells ( Supplementary  Fig. 2 online) . During lymphocyte development, precursor cells had high expression of miR-17-92 miRNA molecules and expression was decreased by 50-70% after maturation (Fig. 1a) . Consistent with earlier reports, examination of a few lymphoma cell lines showed that some had higher expression of miR-17-92 miRNA molecules than did human splenocytes, with the highest expression in L1236 cells, a classical Hodgkin's lymphoma cell line (Fig. 1b) .
To investigate whether increased miR-17-92 miRNA was involved in the initiation of lymphomagenesis, we used a gain-of-function genetargeting approach. For this, we inserted a genomic DNA fragment encoding the human miR-17-92 cluster, preceded by the synthetic CAG promoter and a loxP-flanked 'Neo-STOP' cassette, into the ubiquitously expressed Rosa26 locus. We placed an internal ribosomal entry site-enhanced green fluorescent protein cassette flanked with a Flp recombinase-recognition target between the miR-17-92 genomic DNA fragment and the polyadenylation signal (Supplementary Fig. 3 online) . We called this mutant allele the 'miR-17-92 transgene' . We bred mice carrying this allele with mice transgenic for hCD2-iCre to obtain mice expressing hCD2-iCre and one copy of the miR-17-92 transgene (TG) or two copies of the miR-17-92 transgene (TG/TG). The transgene hCD2-iCre induces expression of Cre recombinase in CD25 -CD44 -doublenegative-stage-1 thymocytes and in pro-B cells 24 . After Cre-mediated excision of the 'Neo-STOP' cassette, the CAG promoter drove production of miR-17-92 miRNA in B cell and T cell compartments (Fig. 1c) . Notably, we did not detect expression of enhanced green fluorescent protein in TG or TG/TG mice (data not shown), probably because of high processing efficiency of the primary transcript by the RNaseIII enzyme Drosha, which cuts out the stem-loop structures encoding individual miRNA molecules and therefore destabilizes the RNA fragment encoding enhanced green fluorescent protein 25 . Relative to its expression in L1236 Hodgkin's lymphoma cells (set as 100%), miR-17-5p expression in thymocytes was 41-43% in control mice and 66-68% in TG/TG mice; in mature B cells, it was 29-37% in control mice and 75-85% in TG/TG mice. The two-to threefold higher miR-17-5p expression in mature TG/TG B cells was also present in mature TG/TG T cells (Fig. 1d) . We also measured expression of miR-19 and miR-92 and found their expression in TG/TG lymphocytes was similar to that of miR-17-5p (Fig. 1c) . CD4 + T cells from TG mice had miR-17-92 expression between those of control mice and TG/TG mice (Fig. 1d) , and TG mice had 'milder' phenotypes than the TG/TG mice we focused on here. As demonstrated by our results, in this experimental system, the transgenic miRNA molecules had expression close to but lower than that of L1236 cells. This is a notable result, as we aimed to establish a mouse model with miR-17-92 expression similar to that in human lymphoma cells.
Lymphoproliferative disease in TG/TG mice To determine the effect of the higher miR-17-92 expression in lymphocytes in vivo, we monitored 16 control mice and 25 TG/TG mice for more than 55 weeks. During this period, 23 TG/TG mice (92%) died, whereas all control mice remained healthy (Fig. 2a) . To exclude the possibility that the hCD2-iCre transgene contributed to the phenotype of the TG/TG mice, we examined five hCD2-iCretransgenic mice by flow cytometry and three hCD2-iCre-transgenic mice by in vitro lymphocyte activation. All these mice had phenotypes similar to those of wild type mice. All diseased mice had spleens and lymph nodes enlarged up to 30-fold in terms of weight and cell number relative to those from control mice ( Supplementary Fig. 4 online). Histologically, TG/TG spleens had a much larger white pulp and a smaller red pulp. The follicular structure was almost completely disrupted, with B cells and T cells randomly mixed. The marginal zone structures were also disrupted, as shown by the absence of MOMA-1 + metallophillic macrophages (Fig. 2b) . Lymph nodes of TG/TG mice showed similar alterations (data not shown).
We killed control and TG/TG mice at 5-45 weeks of age and examined lymphocyte subpopulations in bone marrow, thymus, spleen, peripheral and mesenteric lymph nodes, and the peritoneal cavity by flow cytometry. In TG/TG mice younger than 14 weeks of age, B cell development in the bone marrow was similar to that of control mice (data not shown). Thymocyte development was also Mice as young as 5 weeks had an increased number of lymphocytes in the periphery. The expansion of the CD4 + T cell population was the most consistent and substantial change among all lymphocyte subsets, with CD4 + T cell numbers reaching up to 5 Â 10 8 cells per spleen in TG/TG mice. B cells and CD8 + T cell populations were also expanded, but to a lesser degree than the CD4 + T cell pool (Fig. 3a) . Flow Fig. 3b and Supplementary Fig. 6 online). In these relatively old TG/TG mice, more than 40% of CD4 + T cells also expressed CD69, which suggested that they were recently activated 26 (Fig. 3b) . CD4 + T cells in TG/TG lymph nodes had a similar phenotype (data not shown). Cell cycle analysis showed that a greater proportion of TG/TG than control CD4 + T cells were in the S, G2 and M phases of the cell cycle, which indicated that more of the TG/TG CD4 + T cells were proliferating in vivo (Fig. 3c) .
In 5-week-old TG/TG mice, we noted more CD19 + B220 lo CD5 + CD43 + CD23 -B-1a cells in the spleen and peritoneal cavity and fewer marginal zone B cells (Fig. 3b and data not shown) . These changes were also evident in TG mice (data not shown). The expansion of B-1a cell populations persisted in old TG/TG mice, and marginal zone B cells completely disappeared in aged TG/TG mice (Fig. 3b) . We also noted more germinal center B cells in the spleen and peripheral lymph nodes in TG/TG mice over 6-7 weeks of age. Germinal center B cells represented 5-10% of all splenic and lymph node B cells in TG/TG mice older than 8 weeks, compared with 0.2-1.1% in control mice (Fig. 3b) . In TG/TG mice older than 15 weeks, almost all B cells in the spleen and lymph nodes had greater cell size and higher surface expression of Fas and major histocompatibility complex class II molecules, indicative of cellular activation (Fig. 3d) .
TG/TG mice develop autoimmunity
To assess whether deregulation of lymphocyte activation in TG/TG mice led to autoimmunity, we measured total immunoglobulin concentrations and titers of autoantibody to DNA in the serum of control and TG/TG mice. At the age of 8-12 weeks, TG/TG mice had four-to sixfold higher serum concentrations of total immunoglobulin M (IgM), IgG2a, IgG2b and IgG3 than did control mice (Fig. 4a) . At 18-25 weeks, the blood of TG/TG mice contained significantly higher titers of IgG2a, IgG2b and IgG3 autoantibodies to single-and doublestranded DNA than those of control mice of the same age (Fig. 4b) .
Histological analysis showed massive infiltration of lymphocytes into nonlymphoid tissues of diseased TG/TG mice, with salivary glands and lungs being the most severely affected organs and kidneys being affected to a lesser degree (Fig. 4c) . All these mice showed extramedullary hematopoiesis due to functional failure of the bone marrow (data not shown), and the kidneys of some TG/TG mice seemed pale. Staining of kidney sections with hematoxylin and eosin or with periodic acid-Schiff stain showed enlarged glomeruli with hypercellularity and mesangial expansion (Fig. 4d) . Immunofluorescence staining showed prominent accumulation of IgG and the C3d component of complement in the mesangium and segmentally in the periphery of the glomeruli of a subset of TG/TG mice, which suggested deposition of immune complexes; control mice had much less prominent staining of IgG and C3d confined to the mesangium ( Fig. 4e and Supplementary Fig. 7 online) . In a very sick TG/TG mouse, the nuclei of tubular cells stained positive for IgG (Fig. 4e) , which suggested tissue attack by antinuclear autoantibody. Some TG/ TG mice had proteinuria, which indicated renal dysfunction in these mice (Supplementary Table 1 online) . Thus, higher expression of miR-17-92 in lymphocytes led to the development of an autoimmune disease that may have eventually caused the premature death of some transgenic mice.
Enhanced proliferation and survival of TG/TG lymphocytes To determine whether the phenotype of TG/TG mice was due to lymphocyte-autonomous mechanisms and to better understand the contribution of individual lymphocyte subsets to the phenotype, we purified naive CD4 + CD62L + T cells ( Supplementary Fig. 8 online) and B-2 cells from the spleens and peripheral lymph nodes of young mice, exposed the cells to various stimuli in culture and analyzed their proliferation and survival. We noted enhanced proliferation and survival of naive TG/TG CD4 + T cells after stimulation with antibody to CD3 (anti-CD3) or with anti-CD3 combined with anti-CD28 ( Fig. 5 and Supplementary Table 2 online) . Control CD4 + T cells stimulated with anti-CD3 and anti-CD28 and TG/TG CD4 + T cells treated with anti-CD3 alone proliferated to a similar extent (Fig. 5b) . This suggested that higher expression of miR-17-92 mimics CD28 engagement, which is known to lead to recruitment and activation of phosphtidylinositol-3-OH kinase 27, 28 .
We also noted enhanced proliferation of TG/TG B-2 cells after activation with anti-IgM or lipopolysaccharide (Fig. 5a) . In addition, the activated TG/TG B cells were more resistant to Fas-mediated cell death ( Supplementary Fig. 9 online) of Fas on B cells in TG/TG mice (Fig. 3b,c) . The enhanced proliferation and survival of both T cells and B cells after activation in the periphery may have led to the lymphoproliferative and autoimmune phenotypes noted in TG/TG mice.
Cytokine expression in TG/TG CD4 + T cells
The higher serum immunoglobulin concentrations in TG/TG mice were not equally distributed across all immunoglobulin isotypes (Fig. 4) . Because involvement of cytokines produced by CD4 + helper T cells in the control of immunoglobulin class switching is well established, we examined the cytokine expression profiles of transgenic CD4 + T cells. Many more CD4 + T cells freshly purified from old TG/TG mice produced interferon-g (IFN-g) and interleukin 10 (IL-10) than did their counterparts from control mice, whereas there was no difference in the number of control and TG/TG cells producing IL-4 and tumor necrosis factor (Fig. 6a) .
When we differentiated CD4 + T cells from young mice in vitro in T helper type 1, T helper type 2 and nonpolarizing conditions, more TG/TG CD4 + T cells produced IL-10 and IFN-g, although the difference in the number of IFN-g-producing cells was not as large as the difference obtained for CD4 + T cells freshly isolated from old mice (Fig. 6b) . Again, we did not find a consistent difference in the number of cells producing IL-4 or tumor necrosis factor (Fig. 6b) . It is known that IFN-g stimulates IgG2a production 29, 30 , IL-4 stimulates IgG1 production 31 and IL-10 stimulates IgG3 production 32 . Therefore, these observations are consistent with the immunoglobulin isotype profile of the TG/TG mice, with more IgG2a, IgG2b and IgG3 but normal IgG1 and IgA (Fig. 4) . We also assessed cytokine concentrations in the blood and did not find substantial differences between TG/TG and control mice ( Supplementary Fig. 10 online) . This suggested that the lymphoproliferative and autoimmune phenotypes of TG/TG mice were not the consequences of a global inflammatory response, which is often accompanied by higher serum concentrations of proinflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor 33 . Instead, these phenotypes probably resulted from activation of T cells and B cells and persistence of these activated cells in the periphery.
The miR-17-92 miRNA molecules downregulate PTEN and Bim
To gain insight into the molecular mechanisms underlying the phenotype of TG/TG mice, we searched for miR-17-92 target genes predicted by bioinformatics [34] [35] [36] and focused on genes known to be involved in autoimmunity and lymphoma. Our immediate attention was drawn to PTEN and Bim, two tumor suppressors regulating lymphocyte proliferation and survival; mutation of their genes results in a predisposition to both autoimmunity and lymphomagenesis. When we searched the approximately 18,000 known mouse mRNA 3¢ untranslated regions (UTRs) for those having at least one site complementary to the miRNA 'seed region' (nucleotides 2-8) for each of the three distinct miRNA molecule families in the miR-17-92 cluster (miR-17, miR-19 and miR-92), we found only 50 distinct mRNA molecules with such 3¢ UTRs, and PTEN and Bim transcripts were among the top 10 when we ranked To test whether miR-17-92 miRNA molecules indeed target PTEN and Bim, we purified CD4 + T cells from the spleen and peripheral lymph nodes and measured PTEN and Bim by immunoblot analysis. Expression of PTEN and Bim in TG/TG CD4 + T cells was on average 65% and 60%, respectively, of that in control CD4 + T cells, thus demonstrating that higher miR-17-92 expression in these cells led to lower expression of these two proteins (Fig. 7a,b) . We also measured PTEN and Bim protein expression by intracellular staining and noted similarly lower expression in naive CD62L + CD44 lo and antigenexperienced CD62L -CD44 + TG/TG CD4 + T cells (data not shown). PTEN and Bim protein concentrations were similarly lower in TG/TG B-2 cells (data not shown). To demonstrate that the inhibitory effect of miR-17-92 on PTEN was mediated by miR-17-92-binding sites on its mRNA, we did luciferase reporter assays in tissue culture and found that miR-17-92 overexpression in NIH3T3 cells decreased the activity of a renilla luciferase reporter gene containing the P1 fragment of the PTEN 3¢ UTR, which contains three putative binding sites for miR-17-5p and miR-19, but it did not decrease the activity of a renilla luciferase reporter gene containing other fragments of the PTEN 3¢ UTR (Fig. 7c,d and Supplementary Table 3 and Supplementary  Fig. 11 online) . Mutational analysis showed that the miR-17-5p site and the second miR-19 site in the P1 fragment were important in mediating the inhibition (Fig. 7c,d) . The involvement of miR-17-5p and miR-19 in inhibiting PTEN expression was further confirmed by upregulation of the renilla luciferase reporter gene containing the P1 fragment of the PTEN 3¢ UTR after sequestration of the endogenous miRNA molecules by antisense locked nucleic acid (LNA) oligonucleotides in transfected HeLa cells (Fig. 7e and Supplementary Fig. 11 ). The upregulation of the reporter activity was higher when both miR-17-5p and miR-19 were sequestered, which suggests that miR-17-5p and miR-19 function cooperatively to suppress PTEN protein expression.
Similar experiments showed that miR-17-92 miRNA molecules inhibited Bim expression through their binding sites in the B3 fragment of the Bim 3¢ UTRs (Fig. 7c,d ). The Bim 3¢ UTR also responded to antisense LNA oligonucleotides specific for miR-19 and miR-92 miRNA molecules, although the effect of miR-92 seemed to be dominant (Fig. 7e) . Our results collectively show that higher miR-17-92 expression in lymphocytes leads to lower expression of PTEN and Bim protein, which probably contributed to the lymphoproliferative and autoimmune phenotypes of TG/TG mice.
To determine the degree to which downregulation of the expression of PTEN and Bim protein contributed to the phenotype of miR-17-92-transgenic mice, we generated and analyzed mice doubly heterozygous for the genes encoding PTEN and Bim (Pten and Bcl2l11; called 'hCD2-iCre;Pten fl/+ ;Bim +/-' here). The hCD2-iCre;Pten fl/+ ; Bim +/-mice did not show any obvious difference in the numbers and activation status of lymphocytes relative to that of littermate control mice at the age of 8 weeks (data not shown). However, at the age of 20-28 weeks, hCD2-iCre;Pten fl/+ ;Bim +/-mice accumulated many more antigen-experienced T cells and germinal center B cells than did control mice (Fig. 8a) , a phenotype similar to but milder than that noted in TG/TG mice (Fig. 3b) . When we compared the numbers of CD4 T cells, CD8 T cells, follicular B cells, marginal zone B cells and B-1 cells, we found no substantial difference in hCD2-iCre;Pten fl/+ ;Bim +/-mice versus control mice (data not shown). Intracellular staining showed lower expression of PTEN and Bim protein in antigen-experienced CD44 + CD62L -CD4 + T cells from hCD2-iCre;Pten fl/+ ;Bim +/-mice, and the extent of the diminution was similar to that in TG/TG mice (Figs. 7a,b and 8b,c) . These results demonstrate that downregulation of PTEN and Bim protein expression contributed to the phenotype of TG/TG mice. However, additional miR-17-92 target genes must be involved to fully produce the mutant phenotype.
DISCUSSION
In this study we investigated the effect of increased expression of the miR-17-92 cluster, an miRNA cluster highly expressed in some human lymphomas, on lymphocytes, and its possible contribution to lymphomagenesis, by genetically producing higher miR-17-92 expression in lymphocytes and identifying two tumor suppressors, PTEN and Bim, as functionally important targets. We propose that the downregulation of PTEN and Bim protein expression by miR-17-92 miRNA molecules contributes to the lymphoproliferative and autoimmune phenotype of miR-17-92-transgenic mice and to the development of lymphoma in patients in which the miR-17-92 coding region is amplified in tumor cells. In TG/TG mice, all B cells and T cells had higher miR-17-92 expression, as it was driven by expression of the hCD2-iCre transgene 24 . Because PTEN and Bim are important in maintaining central and peripheral tolerance 6, 7, 11, 12 , downregulation of PTEN and Bim protein expression could potentially cause the breakdown of both tolerance mechanisms. In vitro activation assays showed that TG/TG CD4 + T cells proliferated more and survived better after activation, which suggested the breakdown of peripheral T cell tolerance mechanisms. Whether peripheral B cell tolerance mechanisms and central tolerance mechanisms are intact in TG/TG mice remains to be tested in separate experiments before a firm conclusion can be reached. However, in a first approach, we examined the percentage of bone marrow Hardy fraction E cells, and transitional and mature splenic B cells expressing immunoglobulin l-chain proteins, whose selective loss during B cell maturation has been attributed to negative selection 38 . We did not find any substantial difference between control and TG/TG mice (data not shown), which suggests that negative selection of autoreactive B cells during development is intact in TG/TG mice. We also examined the number of Foxp3 + regulatory CD4 + T cells in the thymus and the spleen and did not find any substantial difference between control and TG/TG mice (data not shown). Therefore, it is likely that higher miR-17-92 expression leads to a breakdown of T cell tolerance in the periphery, causing the accumulation of activated CD4 + T cells, which provide sufficient help to stimulate B cells to enter germinal center reactions, where they undergo class-switch recombination and somatic hypermutation. Some of these cells may differentiate into plasma cells and produce the autoantibodies that we detected in the serum of TG/TG mice. Deposition of IgG immune complexes caused tissue damage, as shown by histological analysis. Similar observations have been reported for sanroque mice, which carry a point mutation in the roquin gene. In sanroque mice, accumulation of activated CD4 + T cells leads to B cell activation, germinal center reactions and autoantibody production 39 . TG/TG mice may die of autoimmune disease before TG/TG lymphocytes accumulate sufficient oncogenic mutations for malignant transformation. In lymphoma patients carrying amplifications of the miR-17-92 coding region in the tumor cells, this amplification probably occurs somatically in individual B cells or T cells during the course of their malignant transformation. Such an amplification will not give rise to systemic autoimmune disease similar to that noted in TG/TG mice. However, cells with higher miR-17-92 expression have a lower threshold for activation, proliferate more and survive better after antigen recognition. These features could lead to an expansion of the mutant cell population, which would increase the probability that such cells, rather than their unmutated counterparts, acquire additional oncogenic mutations. Higher miR-17-92 expression may also 'cooperate' with pre-existing oncogenic mutations.
The molecular mechanisms proposed above may also explain the accelerated lymphomagenesis noted after retroviral expression of miR-17-92 in 'Em-Myc-transgenic' mice 22 . Bim functions as a tumor suppressor in such transgenic mice, and Bim protein expression is higher in Em-Myc-transgenic B cells and mediates apoptosis. The loss of one allele of the gene encoding Bim accelerates c-Myc-induced lymphoma development almost as effectively as the loss of both alleles 8 . Retroviral expression of miR-17-92 accelerates c-Myc-induced lymphoma development to the same degree as the loss of one allele of the gene encoding Bim 22 . We measured Bim concentrations in lymphocytes of Bim +/-mice by immunoblot; the 50% diminution we noted was close to that caused by higher miR-17-92 expression in TG/TG mice. This suggests that downregulation of Bim protein expression by miR-17-92 is a chief mechanism underlying the accelerated c-Myc-mediated lymphomagenesis induced by miR-17-92.
How do miR-17-92 miRNA molecules control PTEN and Bim protein expression? Both PTEN and Bim 3¢ UTRs contain many binding sites for miR-17-92 miRNA molecules, and they are among the top ten targets when mRNA molecules containing at least one site for each of the distinct miRNA families in the miR-17-92 cluster are ranked by the total number of binding sites for these miRNA molecules. On the basis of the results of the reporter assays in NIH3T3 cells overexpressing miR-17-92 and in HeLa cells with individual miR-17-92 miRNA molecules sequestered by antisense LNA oligonucleotides, the first miR-17-5p site and the second miR-19 site in the P1 fragment act cooperatively to mediate repression of PTEN protein. For the Bim 3¢ UTR, the two miR-92 sites seem to dominate. These observations are notable in that they confirm the idea derived from published bioinformatic analyses that coexpressed miRNA molecules may act cooperatively to suppress a common target gene bearing binding sites for these miRNA molecules 34 . They also suggest that not all miRNA-binding sites are functional in a given cellular context. Studies have shown that the context or accessibility of miRNA-binding sites and the protein factors binding in close proximity of the sites strongly influence the function of individual sites [40] [41] [42] . It is therefore possible that nonfunctional sites in NIH3T3 and/or HeLa cells could be functional in lymphocytes or other cells. Alternatively, the expression of other miRNA molecules with identical 'seed regions' could confer functional redundancy in the cells in which we did reporter assays.
To what degree does downregulation of PTEN and Bim protein contribute to the phenotype of TG/TG mice? The hCD2-iCre; Pten fl/+ ;Bim +/-mice had an abnormal, progressive accumulation of antigen-experienced CD4 + T cells and germinal center B cells, similar to those of TG/TG mice. However, the massive lymphocyte population expansion found in the latter mice did not occur in hCD2-iCre; Pten fl/+ ;Bim +/-mice. Therefore, additional miR-17-92 target genes must be taken into account to fully explain the phenotype of TG/TG mice. E2F family transcription factors have been suggested as functional targets of miRNA molecules in the miR-17-92 cluster 43, 44 . E2F1 and E2F2 are important cell cycle regulators, and a decrease in their protein expression leads to the development of hematopoietic malignancy and autoimmunity [45] [46] [47] [48] . It is thus conceivable that downregulation of E2F1 and E2F2 protein acts in synergy with that of PTEN and Bim in causing the severely deleterious disease of TG/TG mice. Because of the unavailability of suitable antibodies to mouse E2F1 and E2F2, we were unable to directly test this hypothesis.
Our data collectively indicate that TG/TG mice develop a notable lymphoproliferative and autoimmune disease. PTEN and Bim were direct targets of miRNA molecules in the miR-17-92 cluster, and hCD2-iCre;Pten fl/+ ;Bim +/-mice had part of the phenotype of TG/TG mice, which demonstrated that miR-17-92-mediated downregulation of PTEN and Bim protein expression indeed contributed to the disease phenotype in TG/TG mice. However, miR-17-92 overexpression affects additional pathways in the cells, whose deregulation, together with that of PTEN and Bim, is required for the massive population expansion found in TG/TG mice. As for lymphomagenesis, our results suggest that miR-17-92 overexpression may well be involved in early phases of disease.
METHODS
Mice. For the generation of miR-17-92-transgenic mice, a genomic DNA fragment from Jurkat cells encoding miR-17-92 was cloned into a modified version of pROSA26-1 as described 49 , preceded by the CAG promoter and a loxP-flanked 'Neo-STOP' cassette, followed by an internal ribosomal entry siteenhanced green fluorescent protein cassette flanked with a Flp recombinaserecognition target, and a polyadenylation signal. Gene targeting was done according to established protocols in the laboratory with Bruce 4 embryonic stem cells. Mice were generated by injection of targeted embryonic stem cells into blastocysts from C57BL/6 albino mice. Mice carrying the targeted allele were bred with hCD2-iCre mice, which deleted the 'Neo-STOP' cassette in both B and T lymphocytes. The hCD2-iCre mice were originally generated by pronuclei injection of fertilized oocytes from (CBA/CaxC57F7BL/10) F 1 mice 24 and were imported from a third party without knowledge of the breeding history. Therefore, the experimental mice were maintained on a mixed genetic background. Mice with conditional knockout of PTEN were from the Jackson Laboratory (006068) and were maintained on a mixed genetic background. Bim-deficient mice were generated as described and were maintained on a mixed genetic background 7 . For all experiments, littermates were used as control (including wild-type mice, hCD2-iCre mice, and mice with one copy or two copies of the miR-17-92 transgene but without any Cre transgene). All mouse experiments were approved by the Institutional Animal Care and Use Committee of Harvard University and by the Immune Disease Institute.
In vitro lymphocyte activation. B-2 cells from spleen and peripheral lymph nodes were purified by depletion of CD43 + cells with magnetic-activated cell sorting (Miltenyi Biotech) and were activated in vitro at a density of 1 Â 10 6 cells per ml with goat anti-mouse IgM (m-chain-specific F(ab¢) 2 fragment; 10 mg/ml; 115-006-020; Jackson Immunoresearch) or with lipopolysaccharide (20 mg/ml; Sigma). CD4 + CD62L + naive T cells from spleens and peripheral lymph nodes were purified by magnetic-activated cell sorting with the CD4 + CD62L + T cell isolation kit (Miltenyi Biotech) and were activated in vitro at a density of 5 Â 10 5 cells per ml with anti-CD3 (0.25 mg/ml; 145.2C11; eBioscience), either alone or in combination with anti-CD28 (2 mg/ml; 37.51; eBioscience), in wells previously coated with goat anti-hamster (0.3 mg/ml; 127-005-160; Jackson Immunoresearch).
Proliferation assay. Purified B-2 cells or CD4 + CD62L + naive T cells were labeled for 10 min at 37 1C with 1 nM CFSE (carboxyfluorescein diacetate succinimidyl diester), followed by two washes with culture medium. Labeled cells were then activated for 2-3 d as described above. Proliferation was monitored by flow cytometry and data were analyzed with FlowJo software.
In vitro differentiation of CD4 + T cells. Total CD4 + T cells from the spleens of old mice (for immediate cytokine staining) or CD4 + CD62L + T cells from the spleens and lymph nodes of young mice (for in vitro T cell differentiation) were purified with magnetic beads (Miltenyi Biotech). For 'neutral' differentiation, cells (5 Â 10 5 cells per ml) were stimulated for 3 d with anti-CD3 (0.25 mg/ml) and anti-CD28 (0.25 mg/ml; 145.2C11 and 37.51, respectively; eBioscience) in a flask coated with goat anti-hamster (0.3 mg/ml; Jackson Immunoresearch) in DMEM supplemented with 10% (vol/vol) FCS, L-glutamine, penicillinstreptomycin, nonessential amino acids, sodium pyruvate, vitamins, HEPES and 2-mercaptoethanol. For T helper type 1 differentiation, cells were stimulated in the presence of recombinant mouse IL-12 (10 ng/ml; Peprotech) and purified anti-IL-4 (10 mg/ml; 11B11; eBioscience). For T helper type 2 differentiation, cells were stimulated in the presence of recombinant mouse IL-4 (25 ng/ml; R&D Systems), anti-IFN-g (5 mg/ml; XMG1.2 or R4-6A2; eBiosciences) and anti-IL-12 (3 mg/ml; C17.8; eBioscience). Populations were subsequently expanded for 2 d in the absence of anti-CD3 and anti-CD28 but in the continued presence of cytokines and antibodies that included recombinant mouse IL-2 (10 ng/ml; Peprotech). Cells were then treated for 6 h with PMA (phorbol 12-myristate 13-acetate; 10-20 nM) and ionomycin (1 mM; Sigma), with the final 4 h in the presence of brefeldin A (5 mg/ml; Sigma) to block cytokine secretion. Restimulated cells were fixed for 8 min at 25 1C in 2% (vol/vol) formaldehyde (Sigma-Aldrich), were stained in permeabilization buffer (0.5% (wt/vol) saponin) and were analyzed by flow cytometry.
Intracellular PTEN and Bim staining. The Foxp3 staining protocol and buffers from eBioscience, PTEN-specific monoclonal antibody (C38G6; Cell Signaling) and mouse Bim-specific monoclonal antibody (Y36; 1036-1; Epitomics) were used for intracellular staining of PTEN and Bim. Freshly isolated splenocytes were stained for surface markers and were fixed for 45 min at 4 1C with fixation and permeabilization buffer. Cells were washed in permeabilization buffer once and were incubated for 45 min at 4 1C in the dark with primary antibody diluted in permeabilization buffer; anti-PTEN was used at a dilution of 1:1,500 and anti-Bim was used at a dilution of 1:200. Subsequently, cells were washed twice with permeabilization buffer and were incubated for 15 min at 4 1C in the dark with allophycocyanin-conjugated secondary antibody at a dilution of 1:500. Cells were washed with flow cytometry buffer and analyzed by flow cytometry.
Statistics. P values were determined with the Student's two-tailed t-test for independent samples, assuming equal variances on all experimental datasets. Table 4 online), histology, cell counts and viability, flow cytometry, cell cycle analysis, ELISA, Fas-mediated cell death assay, immunoblots, luciferase reporter assay, serum cytokine measurements, urine protein measurements is available in the Supplementary Methods online.
Additional methods. Information on RNA blots (Supplementary
Accession codes. UCSD-Nature Signaling Gateway (http://www.signalinggateway.org): A001941 and A003649.
Note: Supplementary information is available on the Nature Immunology website.
